AbbVie (ABBV) Competitors

$202.81 +1.26 (+0.62%)

Closing price 03:59 PM Eastern

Extended Trading

$203.00 +0.19 (+0.09%)

As of 05:06 PM Eastern

ABBV vs. AMGN, GILD, MRNA, ABT, and AZN

Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), and Astrazeneca (AZN).

How does AbbVie compare to Amgen?

AbbVie (NYSE:ABBV) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Amgen has a net margin of 20.96% compared to AbbVie's net margin of 5.79%. Amgen's return on equity of 137.41% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-911.57%	13.43%
Amgen	20.96%	137.41%	13.28%

In the previous week, AbbVie had 18 more articles in the media than Amgen. MarketBeat recorded 61 mentions for AbbVie and 43 mentions for Amgen. AbbVie's average media sentiment score of 1.16 beat Amgen's score of 0.89 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	42 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	27 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

70.2% of AbbVie shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AbbVie has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.

AbbVie presently has a consensus target price of $252.90, suggesting a potential upside of 24.70%. Amgen has a consensus target price of $357.12, suggesting a potential upside of 8.35%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.4%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.1%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 70.1% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Amgen has increased its dividend for 14 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has lower revenue, but higher earnings than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$62.82B	5.71	$4.23B	$2.03	99.91
Amgen	$37.22B	4.78	$7.71B	$14.37	22.94

Summary

AbbVie beats Amgen on 12 of the 20 factors compared between the two stocks.

How does AbbVie compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Gilead Sciences had 11 more articles in the media than AbbVie. MarketBeat recorded 72 mentions for Gilead Sciences and 61 mentions for AbbVie. AbbVie's average media sentiment score of 1.16 beat Gilead Sciences' score of 0.68 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	31 Very Positive mention(s)	11 Positive mention(s)	8 Neutral mention(s)	12 Negative mention(s)	2 Very Negative mention(s)	Positive
AbbVie	42 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences presently has a consensus target price of $157.04, suggesting a potential upside of 17.61%. AbbVie has a consensus target price of $252.90, suggesting a potential upside of 24.70%. Given AbbVie's stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.86
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Gilead Sciences has a net margin of 30.99% compared to AbbVie's net margin of 5.79%. Gilead Sciences' return on equity of 48.19% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
AbbVie	5.79%	-911.57%	13.43%

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.4%. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has increased its dividend for 10 consecutive years and AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.

Gilead Sciences has higher earnings, but lower revenue than AbbVie. Gilead Sciences is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.74B	5.57	$8.51B	$7.34	18.19
AbbVie	$62.82B	5.71	$4.23B	$2.03	99.91

Summary

Gilead Sciences and AbbVie tied by winning 10 of the 20 factors compared between the two stocks.

How does AbbVie compare to Moderna?

AbbVie (NYSE:ABBV) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

AbbVie has a net margin of 5.79% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-911.57%	13.43%
Moderna	-143.55%	-26.64%	-19.32%

AbbVie currently has a consensus target price of $252.90, suggesting a potential upside of 24.70%. Moderna has a consensus target price of $35.73, suggesting a potential downside of 32.43%. Given AbbVie's stronger consensus rating and higher probable upside, equities research analysts plainly believe AbbVie is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$62.82B	5.71	$4.23B	$2.03	99.91
Moderna	$2.20B	9.52	-$2.82B	-$8.15	N/A

70.2% of AbbVie shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AbbVie has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.

In the previous week, AbbVie had 17 more articles in the media than Moderna. MarketBeat recorded 61 mentions for AbbVie and 44 mentions for Moderna. AbbVie's average media sentiment score of 1.16 beat Moderna's score of 0.52 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	42 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	20 Very Positive mention(s)	9 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AbbVie beats Moderna on 12 of the 17 factors compared between the two stocks.

How does AbbVie compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, AbbVie had 29 more articles in the media than Abbott Laboratories. MarketBeat recorded 61 mentions for AbbVie and 32 mentions for Abbott Laboratories. AbbVie's average media sentiment score of 1.16 beat Abbott Laboratories' score of 1.04 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	20 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
AbbVie	42 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Abbott Laboratories has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.

Abbott Laboratories presently has a consensus target price of $119.43, indicating a potential upside of 44.63%. AbbVie has a consensus target price of $252.90, indicating a potential upside of 24.70%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Abbott Laboratories has a net margin of 13.90% compared to AbbVie's net margin of 5.79%. Abbott Laboratories' return on equity of 17.62% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
AbbVie	5.79%	-911.57%	13.43%

Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 3.1%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.4%. Abbott Laboratories pays out 70.6% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories has increased its dividend for 54 consecutive years and AbbVie has increased its dividend for 53 consecutive years.

Abbott Laboratories has higher earnings, but lower revenue than AbbVie. Abbott Laboratories is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.24	$6.52B	$3.57	23.13
AbbVie	$62.82B	5.71	$4.23B	$2.03	99.91

Summary

Abbott Laboratories beats AbbVie on 12 of the 20 factors compared between the two stocks.

How does AbbVie compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and AbbVie (NYSE:ABBV) are related large-cap companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, AbbVie had 43 more articles in the media than Astrazeneca. MarketBeat recorded 61 mentions for AbbVie and 18 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 1.24 beat AbbVie's score of 1.16 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	16 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	42 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.

Astrazeneca presently has a consensus price target of $205.33, suggesting a potential upside of 12.87%. AbbVie has a consensus price target of $252.90, suggesting a potential upside of 24.70%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Astrazeneca has a net margin of 17.19% compared to AbbVie's net margin of 5.79%. Astrazeneca's return on equity of 30.86% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
AbbVie	5.79%	-911.57%	13.43%

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.4%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.4%. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Astrazeneca has higher earnings, but lower revenue than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.80	$10.23B	$6.66	27.31
AbbVie	$62.82B	5.71	$4.23B	$2.03	99.91

Summary

AbbVie beats Astrazeneca on 14 of the 20 factors compared between the two stocks.

Get AbbVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABBV vs. The Competition

Export

Metric	AbbVie	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$358.60B	$289.19B	$6.18B	$22.92B
Dividend Yield	3.41%	2.83%	2.78%	4.02%
P/E Ratio	99.91	25.83	20.66	28.94
Price / Sales	5.71	4.76	527.03	24.54
Price / Cash	13.31	12.33	27.81	19.21
Price / Book	-110.82	7.28	9.77	4.65
Net Income	$4.23B	$11.61B	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-1.20%
1 Month Performance	-2.60%	-1.91%	6.33%	3.96%
1 Year Performance	10.04%	22.86%	41.88%	28.96%

AbbVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABBV AbbVie	4.9387 of 5 stars	$202.81 +0.6%	$252.90 +24.7%	+9.2%	$358.60B	$62.82B	99.91	57,000	Positive News Analyst Upgrade Analyst Revision
AMGN Amgen	4.3839 of 5 stars	$329.56 -4.8%	$357.00 +8.3%	+24.8%	$177.86B	$36.75B	23.16	31,500	Analyst Revision
GILD Gilead Sciences	4.6651 of 5 stars	$131.06 +0.2%	$157.35 +20.1%	+35.6%	$162.66B	$29.44B	19.36	17,000	Earnings Report Dividend Announcement Analyst Forecast
MRNA Moderna	1.3375 of 5 stars	$45.25 -1.5%	$33.87 -25.2%	+124.1%	$17.80B	$1.94B	N/A	4,700	Gap Up
ABT Abbott Laboratories	4.9925 of 5 stars	$89.70 -1.2%	$119.43 +33.1%	-36.9%	$156.25B	$44.33B	25.13	115,000	Positive News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ABBV) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Competitors